|Bid||41.62 x 1000|
|Ask||41.75 x 800|
|Day's range||41.33 - 44.76|
|52-week range||11.64 - 146.16|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||N/A|
|Earnings date||21 Mar 2022 - 25 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||13 Dec 2012|
|1y target est||159.25|
Biogen (BIIB) stock declines after Medicare proposes covering FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in qualifying clinical studies.
First, the company produced strong results in clinical studies for its potential therapy for Alzheimer's disease (AD), Simufilam. The other reason is the result of Biogen, a competitor, receiving regulatory approval in the U.S. last year for its novel AD treatment -- the first such therapy approved for AD since 2003.
A key clinical trial, an enormous market opportunity, and breakthrough biotechnology could drive returns for shareholders this year.